Luca Richeldi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1722120/publications.pdf

Version: 2024-02-01

312 papers	39,367 citations	13827 67 h-index	2883 190 g-index
320 all docs	320 docs citations	320 times ranked	22064 citing authors

#	Article	IF	Citations
1	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.4	26
2	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. European Respiratory Journal, 2022, 59, 2004538.	3.1	47
3	Epidemiology and Diagnosis of Idiopathic Pulmonary Fibrosis. , 2022, , 189-198.		0
4	CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respiratory Research, 2022, 9, e001060.	1.2	17
5	Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1084-1092.	2.5	10
6	Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis. European Respiratory Journal, 2022, 59, 2200024.	3.1	1
7	The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 867-869.	2.5	3
8	Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis. ELife, 2022, 11, .	2.8	31
9	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
10	Advances with pharmacotherapy for the treatment of interstitial lung disease. Expert Opinion on Pharmacotherapy, 2022, 23, 483-495.	0.9	0
11	Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 863-867.	1.5	2
12	Reticulation Is a Risk Factor of Progressive Subpleural Nonfibrotic Interstitial Lung Abnormalities. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 178-185.	2.5	14
13	COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 219-221.	2.5	16
14	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	2.5	780
15	Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2022, 386, 2178-2187.	13.9	77
16	Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study. Respiration, 2022, 101, 775-783.	1.2	7
17	Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research, 2022, 23, .	1.4	17
18	Novel insights in fibrotic pulmonary sarcoidosis. Current Opinion in Pulmonary Medicine, 2022, 28, 478-484.	1.2	2

#	Article	IF	Citations
19	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 211-220.	2.5	55
20	Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Advances in Therapy, 2021, 38, 854-867.	1.3	53
21	Ventilatory Support in Patients with COVID-19. Advances in Experimental Medicine and Biology, 2021, 1318, 469-483.	0.8	0
22	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 550-566.	3.6	53
23	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respiratory Research, 2021, 22, 84.	1.4	33
24	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. Chest, 2021, 159, 1107-1125.	0.4	53
25	An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2021, 20, 1035-1048.	1.0	6
26	Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?. Cells, 2021, 10, 1203.	1.8	18
27	Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. Expert Opinion on Emerging Drugs, 2021, 26, 93-101.	1.0	6
28	Looking Ahead. Clinics in Chest Medicine, 2021, 42, 375-384.	0.8	2
29	Residual respiratory impairment after COVID-19 pneumonia. BMC Pulmonary Medicine, 2021, 21, 241.	0.8	23
30	Bidirectional epithelialâ€“mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis. Journal of Biological Chemistry, 2021, 297, 101096.	1.6	24
31	Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study. Annals of the American Thoracic Society, 2021, 18, 1743-1746.	1.5	0
32	Phase three clinical trials in idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2021, 9, 1-11.	0.5	2
33	Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India, 2021, 38, 41.	0.3	69
34	Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis. Internal and Emergency Medicine, 2021, 16, 349-357.	1.0	5
35	COVID-related fibrosis: insights into potential drug targets. Expert Opinion on Investigational Drugs, 2021, 30, 1183-1195.	1.9	7
36	From pulmonary susceptible tuberculosis to extensively drug resistant tuberculosis: An interesting case report of a young Indian girl. Indian Journal of Tuberculosis, 2020, 67, 340-342.	0.3	1

#	Article	IF	Citations
37	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2020, 8, 25-33.	5.2	165
38	Twentyâ€five years of Respirology: Advances in idiopathic pulmonary fibrosis. Respirology, 2020, 25, 20-22.	1.3	6
39	Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. Multiple Sclerosis and Related Disorders, 2020, 37, 101450.	0.9	8
40	Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. Advances in Therapy, 2020, 37, 4209-4219.	1.3	21
41	Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?. ERJ Open Research, 2020, 6, 00120-2020.	1.1	15
42	Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal?. European Journal of Internal Medicine, 2020, 80, 12-13.	1.0	1
43	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	5.2	198
44	Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends. BMC Pulmonary Medicine, 2020, 20, 249.	0.8	7
45	Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement. Diagnostics, 2020, 10, 664.	1.3	15
46	Treatment strategies for asthma: reshaping the concept of asthma management. Allergy, Asthma and Clinical Immunology, 2020, 16, 75.	0.9	55
47	Current Diagnosis and Management of Hypersensitivity Pneumonitis. Tuberculosis and Respiratory Diseases, 2020, 83, 122.	0.7	20
48	Reply to Fenton et al.: An Expanded COVID-19 Telemedicine Intermediate Care Model Using Repurposed Hotel Rooms. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1192-1193.	2.5	0
49	Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management. Lung, 2020, 198, 429-440.	1.4	23
50	Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study. Respirology, 2020, 25, 1274-1282.	1.3	5
51	Challenges in COVID-19: is pulmonary thromboembolism related to overall severity?. Infectious Diseases, 2020, 52, 585-589.	1.4	4
52	Telemedicine-enabled Accelerated Discharge of Patients Hospitalized with COVID-19 to Isolation in Repurposed Hotel Rooms. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 508-510.	2.5	21
53	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. Respirology, 2020, 25, 1144-1151.	1.3	6
54	Rising to the Challenge of COVID-19: Advice for Pulmonary and Critical Care and an Agenda for Research. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1019-1022.	2.5	32

#	Article	IF	Citations
55	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology, 2020, 296, 172-180.	3.6	721
56	Possible Role of Chest Ultrasonography for the Evaluation of Peripheral Fibrotic Pulmonary Changes in Patients Affected by Idiopathic Pulmonary Fibrosisâ€"Pilot Case Series. Applied Sciences (Switzerland), 2020, 10, 1617.	1.3	7
57	Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€"subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respiratory Medicine,the, 2020, 8, 453-460.	5.2	331
58	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respiratory Medicine,the, 2020, 8, 726-737.	5.2	279
59	Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic. Journal of Ultrasound, 2020, 23, 449-456.	0.7	29
60	Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. Cell Death Discovery, 2020, 6, 54.	2.0	23
61	Progressive Fibrosing Interstitial Lung Disease. A Proposed Integrated Algorithm for Management. Annals of the American Thoracic Society, 2020, 17, 1199-1203.	1.5	6
62	Antibody-based therapies for idiopathic pulmonary fibrosis. Expert Opinion on Biological Therapy, 2020, 20, 779-786.	1.4	13
63	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2020, 20, 3.	0.8	61
64	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
65	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic. Chest, 2020, 158, 106-116.	0.4	832
66	Restless legs syndrome: A new comorbidity in idiopathic pulmonary fibrosis. Respiratory Medicine, 2020, 170, 105982.	1.3	3
67	Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 771-777.	1.9	40
68	Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 169-178.	0.2	5
69	New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases. Tuberculosis and Respiratory Diseases, 2020, 83, 195-200.	0.7	2
70	Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you donâ€™t. Annals of Translational Medicine, 2020, 8, 1615-1615.	0.7	0
71	Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new. Breathe, 2020, 16, 200223.	0.6	0
72	Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?. Jornal Brasileiro De Pneumologia, 2020, 46, e20200193-e20200193.	0.4	0

#	Article	IF	Citations
73	Paracrine signalling during ZEB1-mediated epithelialâ€“mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death and Differentiation, 2019, 26, 943-957.	5.0	104
74	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21.	2.5	102
75	Autophagy inhibition-mediated epithelialâ€“mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death and Disease, 2019, 10, 591.	2.7	107
76	Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. Respiratory Medicine, 2019, 156, 20-25.	1.3	22
77	Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey. European Respiratory Journal, 2019, 54, 1900906.	3.1	5
78	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respiratory Medicine,the, 2019, 7, 657-664.	5.2	73
79	Statin Therapy and Lung Disorders. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 921-923.	2.5	1
80	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
81	SAFETY OF NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): LONG-TERM GLOBAL PHARMACOVIGILANCE DATA. Chest, 2019, 156, A1011-A1012.	0.4	0
82	Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 941-942.	2.5	3
83	The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1089-1092.	2.5	45
84	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2019, 381, 1718-1727.	13.9	1,338
85	Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 121-123.	2.5	13
86	X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology. American Journal of Pathology, 2019, 189, 1608-1620.	1.9	57
87	The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1900539.	3.1	8
88	Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 261-263.	2.5	11
89	The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities. American Journal of the Medical Sciences, 2019, 357, 405-410.	0.4	1
90	Contemporary Concise Review 2018: Interstitial lung disease. Respirology, 2019, 24, 809-816.	1.3	6

#	Article	IF	Citations
91	New Frontiers in Ultrasonography of the Mediastinum: Pediatric EBUS-TBNA. Respiratory Care, 2019, 64, 358.2-359.	0.8	2
92	Impact of chest imaging quality on theÂdiagnosis of the usual interstitial pneumonia pattern: a hub and spokeÂstudy. European Respiratory Journal, 2019, 53, 1900084.	3.1	2
93	Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 133-139.	2.5	10
94	Update in Pulmonary Fibrosis 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 292-300.	2.5	23
95	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Research, 2019, 5, 00127-2018.	1.1	21
96	Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. BMC Infectious Diseases, 2019, 19, 215.	1.3	7
97	Current and Future Idiopathic Pulmonary Fibrosis Therapy. American Journal of the Medical Sciences, 2019, 357, 370-373.	0.4	13
98	Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: preliminary results. Multidisciplinary Respiratory Medicine, 2019, 14, 9.	0.6	14
99	Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respiratory Research, 2019, 6, e000397.	1.2	121
100	Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSISÂ® trials. Respiratory Research, 2019, 20, 71.	1.4	30
101	Novel drug targets in idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2019, 7, 125-146.	0.5	1
102	The characterisation of interstitial lungÂdisease multidisciplinary team meetings:ÂaÂglobal study. ERJ Open Research, 2019, 5, 00209-2018.	1.1	49
103	Reply to Moodley and to Ravaglia et al.. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 667-669.	2.5	0
104	Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 39-51.	1.0	25
105	Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis:Âa prospective pilot study. European Respiratory Journal, 2019, 53, 1802093.	3.1	12
106	No relevant pharmacokinetic drugâ€“drug interaction between nintedanib and pirfenidone. European Respiratory Journal, 2019, 53, 1801060.	3.1	22
107	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	1.3	34
108	Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial. , 2019, , .		1

#	Article	IF	Citations
109	Pharmacologic Treatment of IPF. Respiratory Medicine, 2019, , 325-364.	0.1	1
110	Late Breaking Abstract - Investigation of the epithelial-mesenchymal paracrine interactions in lung tissue repair and fibrosis. , 2019, , .		0
111	Interstitial pneumonia with autoimmune features (IPAF): a clinical entity?. , 2019, , .		0
112	What proportion of patients with Idiopathic Pulmonary Fibrosis fall outside UK prescribing criteria for anti-fibrotic treatment? A UK specialist centre review. , 2019, , .		0
113	Impact of comorbidities in interstitial pneumonia with autoimmune features (IPAF). , 2019, , .		0
114	Prognostic role of ultrasonographic air bronchogram in management of pneumoniae in children. , 2019, , .		2
115	Possible role of chest ultrasonography for the evaluation of peripheral fibrotic changes in patients affected by IPF. , 2019, , .		0
116	Hypoxia-inducible factor pathway activation promotes bone-type collagen cross-linking in Idiopathic Pulmonary Fibrosis. , 2019, , .		1
117	Diagnostic criteria for idiopathic pulmonary fibrosis â€“ Authorsâ€™ reply. Lancet Respiratory Medicine,the, 2018, 6, e7.	5.2	3
118	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	5.2	137
119	Validation of multidisciplinary diagnosis in IPF. Lancet Respiratory Medicine,the, 2018, 6, 88-89.	5.2	13
120	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 317-326.	1.2	42
121	Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Pharmacotherapy, 2018, 19, 167-175.	0.9	53
122	Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax, 2018, 73, 581-583.	2.7	59
123	Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 9-10.	2.5	6
124	Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 356-363.	2.5	193
125	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	2.5	174
126	Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. Radiologia Medica, 2018, 123, 245-253.	4.7	34

#	Article	IF	Citations
127	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	5.2	739
128	Management of Idiopathic Pulmonary Fibrosis. , 2018, , 55-63.		1
129	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research, 2018, 4, 00049-2018.	1.1	24
130	Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European Respiratory Review, 2018, 27, 180074.	3.0	73
131	Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 1359-1370.	0.4	44
132	Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations. Molecular Diagnosis and Therapy, 2018, 22, 723-728.	1.6	12
133	Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis. Current Pulmonology Reports, 2018, 7, 107-117.	0.5	2
134	SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). European Respiratory Journal, 2018, 52, 1801130.	3.1	59
135	Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidisciplinary Respiratory Medicine, 2018, 13, 39.	0.6	17
136	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731.	13.9	207
137	Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies. European Respiratory Journal, 2018, 52, 1801485.	3.1	23
138	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
139	Optimising experimental research in respiratory diseases: an ERS statement. European Respiratory Journal, 2018, 51, 1702133.	3.1	98
140	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2018, 319, 2299.	3.8	170
141	Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1702593.	3.1	29
142	Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. ELife, 2018, 7, .	2.8	99
143	Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. European Journal of Heart Failure, 2018, 20, 1385-1391.	2.9	38
144	â€œVelcro-typeâ€•crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC Pulmonary Medicine, 2018, 18, 103.	0.8	45

#	Article	IF	Citations
145	Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions. Respiratory Care, 2018, 63, 1421-1438.	0.8	8
146	Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1105-1106.	2.5	1
147	Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory Research, 2018, 19, 32.	1.4	339
148	Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial. , 2018, , .		1
149	Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery. , 2018, , .		0
150	Accuracy and safety of EUS-B-FNA in the diagnosis of lung parenchymal lesions. , 2018, , .		0
151	Late Breaking Abstract - Prevalence and clinical significance of antinuclear antibody (ANA) in IPF: analysis from ESTAIR study. , 2018, , .		0
152	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 78-85.	2.5	147
153	Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax, 2017, 72, 340-346.	2.7	191
154	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	2.5	166
155	Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. Respiration, 2017, 93, 379-395.	1.2	22
156	Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1601339.	3.1	109
157	New treatment directions for IPF: current status of ongoing and upcoming clinical trials. Expert Review of Respiratory Medicine, 2017, 11, 533-548.	1.0	13
158	Current approaches to the management of idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 129, 24-30.	1.3	52
159	Idiopathic pulmonary fibrosis. Lancet, The, 2017, 389, 1941-1952.	6.3	1,199
160	Interstitial Lung Disease in India. Keep Searching and Youâ€™ll Keep Finding. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 714-715.	2.5	4
161	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respiratory Medicine,the, 2017, 5, 61-71.	5.2	79
162	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, 2017, 64, e1-e33.	2.9	501

#	Article	IF	Citations
163	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, 2017, 64, 111-115.	2.9	492
164	Managing patients with interstitial lung disease: Two more pieces of the puzzle. Respirology, 2017, 22, 1481-1482.	1.3	1
165	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	18.1	786
166	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
167	Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis. Revista Portuguesa De Pneumologia, 2017, 23, 245-246.	0.7	0
168	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respiratory Research, 2017, 4, e000212.	1.2	151
169	Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?. Expert Opinion on Pharmacotherapy, 2017, 18, 1583-1594.	0.9	4
170	Investigational drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2017, 26, 1019-1031.	1.9	18
171	COPD management as a model for all chronic respiratory conditions: report of the 4th Consensus Conference in Respiratory Medicine. Multidisciplinary Respiratory Medicine, 2017, 12, 28.	0.6	2
172	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
173	Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulmonary Pharmacology and Therapeutics, 2017, 45, 191-201.	1.1	13
174	Challenges in idiopathic interstitial lung disease: an update. Minerva Respiratory Medicine, 2017, 56, .	0.1	1
175	PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients. , 2017, , .		4
176	The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget, 2017, 8, 48737-48754.	0.8	48
177	Global characterisation of routine care interstitial lung disease diagnostic practice. , 2017, , .		0
178	Correlation between lung sounds and HRCT signs of pulmonary fibrosis: a blinded prospective study. , 2017, , .		0
179	Ultrasonographic assessment of diaphragm dysfunction in acute exacerbations of COPD. , 2017, , .		0
180	FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF. , 2017, , .		2

#	Article	IF	Citations
181	Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. Journal of Medical Case Reports, 2016, 10, 127.	0.4	2
182	Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis. Thorax, 2016, 71, 399-400.	2.7	2
183	Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of GAP Stage at Baseline in the INPULSIS Trials. Chest, 2016, 150, 540A.	0.4	0
184	Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient. European Respiratory Journal, 2016, 47, 1057-1059.	3.1	4
185	What if we made stratified medicine work for patients?. Lancet Respiratory Medicine,the, 2016, 4, 8-10.	5.2	12
186	Recent Advances and Future Needs in Interstitial Lung Diseases. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 477-484.	0.8	4
187	Orphan Lung Diseases. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 319-320.	0.8	0
188	Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays. New Microbes and New Infections, 2016, 12, 45-51.	0.8	6
189	Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSISÂ® trials. Respiratory Medicine, 2016, 113, 74-79.	1.3	335
190	Targeted treatment of idiopathic pulmonary fibrosis: one step at a time. European Respiratory Journal, 2016, 47, 1321-1323.	3.1	3
191	Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. Respirology, 2016, 21, 427-437.	1.3	137
192	How we will diagnose IPF in the future. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 581-583.	0.2	3
193	The safety of new drug treatments for idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2016, 15, 1483-1489.	1.0	21
194	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
195	Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1213-1218.	2.5	59
196	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Medicine, 2016, 14, 18.	2.3	79
197	Novel drug targets for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 393-405.	1.0	27
198	Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 178-185.	2.5	209

#	Article	IF	Citations
199	Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight, 2016, 1, .	2.3	73
200	Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis. , 2016, , .		0
201	Sarcoidosis in the UK: Insights from the BTS interstitial lung disease registry. , 2016, , .		0
202	Combining immunostaining with micro-computed tomography to visualise the 3D distribution of mast cells in idiopathic pulmonary fibrosis. , 2016, , .		0
203	First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry. , 2016, , .		1
204	Twenty-four week decline in forced vital capacity predicts mortality at week 52 in the INPULSISÂ® trials. , 2016, , .		2
205	No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib. , 2016, , .		0
206	Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF). , 2016, , .		0
207	Effect of baseline statin use on benefit of nintedanib. , 2016, , .		1
208	Idiopathic pulmonary fibrosis: moving forward. BMC Medicine, 2015, 13, 231.	2.3	4
209	Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine, 2015, 13, 237.	2.3	34
210	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC Medicine, 2015, 13, 277.	2.3	23
211	Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respiratory Research, 2015, 16, 116.	1.4	114
212	Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1020-1021.	2.5	0
213	Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia. ERJ Open Research, 2015, 1, 00020-2015.	1.1	26
214	CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society. Lancet Respiratory Medicine,the, 2015, 3, 483-496.	5.2	149
215	Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. BMJ Open Respiratory Research, 2015, 2, e000065.	1.2	22
216	Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India, 2015, 32, 50.	0.3	31

#	Article	IF	Citations
217	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	2.5	1,521
218	Nintedanib in the treatment of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2015, 9, 121-129.	1.0	57
219	Efficacy endpoints for idiopathic pulmonary fibrosis trials. Lancet Respiratory Medicine,the, 2015, 3, 335-337.	5.2	2
220	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	3.1	48
221	Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. , 2015, 152, 18-27.		74
222	Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A proâ€con perspective. Respirology, 2015, 20, 389-394.	1.3	7
223	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	3.1	803
224	Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough. European Respiratory Journal, 2015, 46, 607-614.	3.1	9
225	Effect of baseline FVC on lung function decline with nintedanib in patients with IPF. , 2015, , .		6
226	Pulmonary Fibrosis and the Many Faces of UIP. , 2015, , 315-325.		0
227	Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation. Annals of the American Thoracic Society, 2015, 12, S181-S185.	1.5	17
228	Purpose of the Conference: 2015 Transatlantic Airway Conference. Annals of the American Thoracic Society, 2015, 12, S111-S111.	1.5	0
229	A Quantitative Proteomic Approach to Identify Significantly Altered Protein Networks in the Serum of Patients with Lymphangioleiomyomatosis (LAM). PLoS ONE, 2014, 9, e105365.	1.1	14
230	Air pollution and acute exacerbations of idiopathic pulmonary fibrosis: back to miasma?. European Respiratory Journal, 2014, 43, 956-959.	3.1	11
231	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014, 69, 436-444.	2.7	100
232	Idiopathic Pulmonary Fibrosis: CT and Risk of Death. Radiology, 2014, 273, 570-579.	3.6	85
233	A global registry for idiopathic pulmonary fibrosis: the time is now. European Respiratory Journal, 2014, 44, 273-276.	3.1	25
234	Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. European Respiratory Review, 2014, 23, 106-110.	3.0	74

#	Article	IF	Citations
235	Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 159-165.	0.8	28
236	Design of the INPULSISâ„¢ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2014, 108, 1023-1030.	1.3	82
237	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	5.2	128
238	Treatments for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 371, 781-784.	13.9	31
239	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2071-2082.	13.9	3,351
240	Fibulin-1 Predicts Disease Progression in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2014, 146, 1055-1063.	0.4	42
241	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. , 2014, , 297-311.		0
242	Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respiratory Research, 2013, 14, 73.	1.4	173
243	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	2.5	3,134
244	Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respiratory Medicine, 2013, 107, 249-255.	1.3	84
245	Lung cancer in scleroderma: Results from an Italian rheumatologic center and review of the literature. Autoimmunity Reviews, 2013, 12, 374-379.	2.5	50
246	Idiopathic pulmonary fibrosis: current challenges and future perspectives. European Respiratory Review, 2013, 22, 103-105.	3.0	8
247	The Reply. American Journal of Medicine, 2013, 126, e19.	0.6	24
248	Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy. Respiration, 2013, 86, 353-363.	1.2	26
249	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
250	A Culture-Proven Case of Community-AcquiredLegionellaPneumonia Apparently Classified as Nosocomial: Diagnostic and Public Health Implications. Case Reports in Medicine, 2013, 2013, 1-4.	0.3	7
251	Prevalence and prognosis of unclassifiable interstitial lung disease. European Respiratory Journal, 2013, 42, 750-757.	3.1	238
252	New approaches to the design of clinical trials in idiopathic pulmonary fibrosis. Clinical Investigation, 2013, 3, 531-544.	0.0	1

#	Article	IF	Citations
253	The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications. Respiratory Research, 2013, 14, S2.	1.4	72
254	Recommendations on treatment for IPF. Respiratory Research, 2013, 14, S6.	1.4	16
255	Clinical trials of investigational agents for IPF: a review of a Cochrane report. Respiratory Research, 2013, 14, S4.	1.4	8
256	The big clinical trials in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2012, 18, 428-432.	1.2	38
257	Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going. Current Respiratory Care Reports, 2012, 1, 216-223.	0.6	0
258	Preface. Clinics in Chest Medicine, 2012, 33, xiii.	0.8	1
259	Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax, 2012, 67, 938-940.	2.7	71
260	Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. European Respiratory Review, 2012, 21, 147-151.	3.0	22
261	Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax, 2012, 67, 407-411.	2.7	160
262	Sarcoidosis: Challenging Diagnostic Aspects of an Old Disease. American Journal of Medicine, 2012, 125, 118-125.	0.6	43
263	The role of biomarkers in low respiratory tract infections. European Journal of Internal Medicine, 2012, 23, 429-435.	1.0	14
264	Genetic testing in diffuse parenchymal lung disease. Orphanet Journal of Rare Diseases, 2012, 7, 79.	1.2	8
265	Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidisciplinary Respiratory Medicine, 2012, 7, 42.	0.6	42
266	Management of Idiopathic Pulmonary Fibrosis. Clinics in Chest Medicine, 2012, 33, 85-94.	0.8	9
267	Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 712-715.	2.5	92
268	Aortic pulse wave velocity measurement in systemic sclerosis patients. Reumatismo, 2012, 64, 360-7.	0.4	17
269	Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. Clinical Respiratory Journal, 2012, 6, 129-130.	0.6	0
270	Pirfenidone. Nature Reviews Drug Discovery, 2011, 10, 489-490.	21.5	47

#	Article	IF	Citations
271	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 788-824.	2.5	6,033
272	Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2011, 365, 1079-1087.	13.9	930
273	Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Review of Respiratory Medicine, 2011, 5, 473-481.	1.0	28
274	Emerging drugs for idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 2011, 16, 341-362.	1.0	21
275	Role of the Quantiferon-TB Test in Ruling Out Pleural Tuberculosis: A Multi-Centre Study. International Journal of Immunopathology and Pharmacology, 2011, 24, 159-165.	1.0	13
276	Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants. , 2011, , .		0
277	Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing [Short communication]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1182-1184.	0.6	7
278	Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis. Multidisciplinary Respiratory Medicine, 2011, 6, 313.	0.6	4
279	A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis, 2011, 91, 260-267.	0.8	113
280	A Decade of Interferon-Î³ Release Assays: Quest for the Holy Grail to Diagnose Latent Infection withMycobacterium tuberculosis?. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1732-1732.	2.5	1
281	Viruses and Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1583-1584.	2.5	9
282	End of an ERA: Lessons from Negative Clinical Trials in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 4-5.	2.5	8
283	The complex interrelationships between chronic lung and liver disease: a review. Journal of Viral Hepatitis, 2010, 17, 381-390.	1.0	24
284	PERFORMANCE OF QUANTIFERON-TB GOLD IN-TUBE IN PATIENTS WITH NON-TUBERCULOUS MYCOBACTERIAL DISEASE. , 2010, , .		1
285	Unexpected identification of bilateral masses in an asymptomatic heavy smoker. Thorax, 2010, 65, 846-846.	2.7	0
286	Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. Scandinavian Journal of Rheumatology, 2010, 39, 155-159.	0.6	2
287	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 102-103.	2.5	6
288	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 289-290.	2.5	2

#	Article	IF	Citations
289	Non-steroid agents for idiopathic pulmonary fibrosis. The Cochrane Library, 2010, , CD003134.	1.5	103
290	ROLE OF QUANTIFERON-TB GOLD TEST IN THE DIAGNOSIS OF ACTIVE TUBERCULOSIS. , 2010, , .		0
291	Amyotrophic lateral sclerosis and sarcoidosis: A difficult differential diagnosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 410-411.	2.3	3
292	Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients. Chest, 2009, 136, 198-204.	0.4	137
293	To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 379-380.	2.5	5
294	Diagnosing Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1-2.	2.5	4
295	Bronchoalveolar Lavage Enzyme-linked Immunospot for a Rapid Diagnosis of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 666-673.	2.5	125
296	Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. Archivum Immunologiae Et Therapiae Experimentalis, 2009, 57, 425-433.	1.0	16
297	Performance of Commercial Blood Tests for the Diagnosis of Latent Tuberculosis Infection in Children and Adolescents. Pediatrics, 2009, 123, e419-e424.	1.0	132
298	Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TBassay. Expert Review of Respiratory Medicine, 2008, 2, 253-260.	1.0	12
299	Environmental Triggers and Susceptibility Factors in Idiopathic Granulomatous Diseases. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 610-619.	0.8	18
300	Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet, The, 2006, 367, 1328-1334.	6.3	468
301	An Update on the Diagnosis of Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 736-742.	2.5	287
302	Routine Hospital Use of a New Commercial Whole Blood Interferon-Î³ Assay for the Diagnosis of Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 631-635.	2.5	240
303	Chronic beryllium disease: a model for pulmonary sarcoidosis?. Acta Biomedica, 2005, 76 Suppl 2, 11-4.	0.2	5
304	T Cellâ€“Based Tracking of Multidrug Resistant Tuberculosis Infection after Brief Exposure. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 288-295.	2.5	131
305	Corticosteroids for idiopathic pulmonary fibrosis. The Cochrane Library, 2003, , CD002880.	1.5	133
306	Immunomodulatory agents for idiopathic pulmonary fibrosis. , 2003, , CD003134.		62

#	Article	IF	Citations
307	Interaction of genetic and exposure factors in the prevalence of berylliosis. , 1997, 32, 337-340.		128
308	Interaction of genetic and exposure factors in the prevalence of berylliosis. American Journal of Industrial Medicine, 1997, 32, 337-340.	1.0	3
309	IPF: treatment and prevention of pulmonary exacerbations. , 0, , 199-223.		0
310	Key ongoing issues in trial design. , 0, , 253-259.		0
311	Reply to: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	0
312	Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region. Frontiers in Medicine, 0, 9, .	1.2	1